Prelude Therapeutics Inc PRLD
Prelude Therapeutics Inc (Nasdaq: PRLD) is an oncology drug developer. Its lead program, PRT12396, is in Phase 1 for polycythemia vera and myelofibrosis (JAK2V617F-mutant MPN). Its next catalyst on record is PRT13722: Phase 1 study of PRT13722 in HR+/HER2- breast cancer anticipated to begin enrolling in Q4 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PRT13722 — Phase 1 study of PRT13722 in HR+/HER2- breast cancer anticipated to begin enrolling in Q4 2026. (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PRT12396 (JAK2V617F mutant-selective inhibitor) | polycythemia vera; myelofibrosis | small molecule | Phase 1 |
| PRT13722 (KAT6A degrader) | HR+/HER2- breast cancer | small molecule | Pre-clinical |
| CALR-targeted degrader antibody conjugates | myeloproliferative neoplasms | antibody | Pre-clinical |
| SMARCA2/4 degrader payload DACs (with AbCellera) | solid tumors | antibody | Pre-clinical |
Recent results and decisions
- Sep 10, 2026accepted FDA cleared IND for PRT13722 Phase 1 study in HR+ breast cancer patients, with enrollment anticipated to begin in fourth quarter 2026.
IND application clearance received; Phase 1 study of PRT13722 in patients with HR+/HER2- breast cancer anticipated to being enrolling in the fourth quarter.
Filing - Sep 10, 2026started Phase 1 dose escalation study of PRT13722 as monotherapy and in combinations expected to start enrolling in fourth quarter 2026.
Phase 1 study of PRT13722 in patients with HR+/HER2- breast cancer anticipated to being enrolling in the fourth quarter.
Filing - Sep 10, 2026started Prelude's Phase 1 study of PRT12396, a JAK2V617F mutant selective inhibitor, is now enrolling MF and PV cohorts in parallel.
MF & PV cohorts enrolling in parallel
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.